Embecta (EMBC) Stock Price, News & Analysis

+0.03 (+0.21%)
(As of 10:46 AM ET)
Today's Range
50-Day Range
52-Week Range
52,948 shs
Average Volume
429,766 shs
Market Capitalization
$835.06 million
P/E Ratio
Dividend Yield
Price Target

Embecta MarketRank™ Stock Analysis

Analyst Rating
1.50 Rating Score
10.2% Downside
$13.00 Price Target
Short Interest
4.81% of Float Sold Short
Dividend Strength
Based on Four Factors
News Sentiment
0.66mentions of Embecta in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From $2.30 to $2.35 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.30 out of 5 stars

Medical Sector

717th out of 918 stocks

Surgical & Medical Instruments Industry

83rd out of 100 stocks

EMBC stock logo

About Embecta Stock (NASDAQ:EMBC)

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

EMBC Stock Price History

EMBC Stock News Headlines

embecta Announces Quarterly Cash Dividend
Embecta earnings preview: what Wall Street is expecting
embecta to Participate in Investor Events
EMBC Apr 2024 10.000 put
EMBC Apr 2024 20.000 call
Embecta (NASDAQ:EMBC) Has Affirmed Its Dividend Of $0.15
Embecta Shareholders Approve Directors and Compensation Plans
Embecta Shares Fall Despite Outlook Raise, Strong 1Q
Embecta Sinks As Outlook Comes In Below Consensus
Why Embecta Stock Is Tanking Today
Why Embecta Stock Is Tanking Today
See More Headlines
Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/15 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 6/14 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$70.40 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.12 billion
Cash Flow
$3.70 per share
Book Value
($14.34) per share


Free Float
Market Cap
$835.06 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Devdatt Kurdikar (Age 56)
    President, CEO & Director
    Comp: $2.2M
  • Mr. Jacob P. Elguicze (Age 51)
    Senior VP & CFO
    Comp: $1.05M
  • Mr. Brian R. Capone (Age 49)
    VP, Chief Accounting Officer & Corporate Controller
    Comp: $645.16k
  • Mr. Jeffrey Z. Mann (Age 52)
    Senior VP, General Counsel, Head of Business Development & Corporate Secretary
    Comp: $959.45k
  • Mr. Shaun Curtis (Age 55)
    Senior Vice President of Global Manufacturing & Supply Chain
    Comp: $915.67k
  • Ms. Colleen Riley (Age 60)
    Senior VP & Chief Technology Officer
  • Mr. Pravesh Khandelwal
    VP & Head of Investor Relations
  • Ms. Ginny Blocki
    Senior Vice President of Global Marketing & Product Management
  • Ms. Jean M. Casner (Age 66)
    Senior VP & Chief Human Resources Officer
  • Mr. Tom Blount (Age 50)
    Senior VP & President of North America

EMBC Stock Analysis - Frequently Asked Questions

Should I buy or sell Embecta stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EMBC shares.
View EMBC analyst ratings
or view top-rated stocks.

What is Embecta's stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for Embecta's shares. Their EMBC share price targets range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next twelve months. This suggests that the stock has a possible downside of 10.2%.
View analysts price targets for EMBC
or view top-rated stocks among Wall Street analysts.

How have EMBC shares performed in 2024?

Embecta's stock was trading at $18.93 at the beginning of the year. Since then, EMBC stock has decreased by 23.5% and is now trading at $14.48.
View the best growth stocks for 2024 here

When is Embecta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our EMBC earnings forecast

How were Embecta's earnings last quarter?

Embecta Corp. (NASDAQ:EMBC) released its quarterly earnings results on Thursday, May, 9th. The company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.24. The business had revenue of $287.20 million for the quarter, compared to analysts' expectations of $264.70 million. Embecta had a negative trailing twelve-month return on equity of 18.42% and a net margin of 6.20%. The company's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 earnings per share.

How often does Embecta pay dividends? What is the dividend yield for Embecta?

Embecta declared a quarterly dividend on Thursday, May 9th. Investors of record on Tuesday, May 28th will be given a dividend of $0.15 per share on Friday, June 14th. This represents a $0.60 dividend on an annualized basis and a yield of 4.14%. The ex-dividend date is Friday, May 24th.
Read our dividend analysis for EMBC

Is Embecta a good dividend stock?

Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 4.15%. EMBC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 49.59%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 25.53% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for EMBC.

What ETFs hold Embecta's stock?

ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include Syntax Stratified SmallCap ETF (SSLY) and Invesco S&P Spin-Off ETF (CSD).Simplify Health Care ETF (PINK).

What guidance has Embecta issued on next quarter's earnings?

Embecta updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of 2.200-2.300 for the period, compared to the consensus EPS estimate of 2.100. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Who are Embecta's major shareholders?

Embecta's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (12.53%), Janus Henderson Group PLC (1.94%), Jacobs Levy Equity Management Inc. (1.12%), First Eagle Investment Management LLC (0.72%), Sei Investments Co. (0.63%) and Principal Financial Group Inc. (0.52%). Insiders that own company stock include David F Melcher, Devdatt Kurdikar, Jacob Elguicze and Jeffrey Z Mann.
View institutional ownership trends

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EMBC) was last updated on 5/20/2024 by Staff

From Our Partners